Skip to main content

Advertisement

Table 3 Diagnosis and treatment characteristics and distribution by LTFU status of adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009–2016 (n = 305)

From: Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009–2016: survival model approach

Diagnosis and Treatment characteristics LTFU (n1 = 45) Frequency (%) No-LTFU (n2 = 260) Frequency (%) Total (n = 305) Frequency (%) LTFU Rate [95%CI] Per 100 PYs P-value
Adverse drug events 0.0087
 No 39 (86.7) 156 (60.0) 192 (63.0) 6.0 [4.4, 8.4]  
 Yes 6 (13.3) 104 (40.0) 113 (37.0) 3.3 [1.2, 4.3]  
History OI/s 0.0180
 No 3 (6.7) 59 (22.7) 62 (20.3) 1.4 [0.5, 4.5]  
 Yes 42 (93.3) 201 (77.3) 243 (79.7) 5.3 [3.9, 7.2]  
TB Category 0.0530
 PTB 16 (35.6) 116 (44.6) 132 (43.3) 3.1 [1.9, 5.1]  
 EPTB/Mixed 29 (64.4) 144 (55.4) 173 (56.7) 6.0 [4.2, 8.7]  
TB treatment completion < 0.001
 No 13 (28.9) 39 (15.0) 52 (17.0) 35.7 [20.7, 61.5]  
 Yes 32 (71.1) 221 (85.0) 253 (83.0) 3.3 [2.4, 4.7]  
IPT 0.0025
 on 1 (2.2) 47 (18.1) 48 (15.7) 5.6 [4.2, 7.6]  
 off 44 (97.8) 213 (81.9) 257 (84.3) 0.5 [0.1, 3.3]  
CPT 0.9189
 Off 7 (15.6) 44 (16.9) 51 (16.7) 4.7 [2.2, 9.8]  
 On 38 (84.4) 216 (83.1) 254 (83.3) 4.5 [3.3, 6.2]  
  1. OI/s opportunistic Infection/s, PTB Pulmonary Tuberculosis, EPTB Extra Pulmonary Tuberculosis, CPT Co-trimoxazole Prophylactic Therapy, IPT Isoniazid Preventive Therapy